Drug Overview: Singulair

  • ID: 4489133
  • Drug Pipelines
  • 16 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Singulair (montelukast; Merck & Co/Kyorin) is an oral leukotriene D4 receptor antagonist used for prophylactic treatment of asthma. The drug is available in several oral formulations and is primarily taken as an add-on therapy for patients with refractory and/or allergic asthma.

1 Product Profiles
  • Singulair: Asthma
List of Figures
Figure 1: Singulair for asthma - SWOT analysis
Figure 2: The author’s drug assessment summary of Singulair in asthma
Figure 3: The author’s drug assessment summary of Singulair in asthma
Figure 4: Singulair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Singulair drug profile
Table 2: Singulair pivotal trial data in asthma
Table 3: Singulair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Note: Product cover images may vary from those shown
2 of 3

Loading
LOADING...

3 of 3
  • Merck & Co
  • Kyorin
Note: Product cover images may vary from those shown
4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll